@article{ada1de221ef146e39e8be7b7e6d6dd3f,
title = "Pyruvate dehydrogenase inactivation causes glycolytic phenotype in BAP1 mutant uveal melanoma",
abstract = "Effective therapeutic options are still lacking for uveal melanoma (UM) patients who develop metastasis. Metastatic traits of UM are linked to BRCA1-associated protein 1 (BAP1) mutations. Cell metabolism is re-programmed in UM with BAP1 mutant UM, but the underlying mechanisms and opportunities for therapeutic intervention remain unclear. BAP1 mutant UM tumors have an elevated glycolytic gene expression signature, with increased expression of pyruvate dehydrogenase (PDH) complex and PDH kinase (PDHK1). Furthermore, BAP1 mutant UM cells showed higher levels of phosphorylated PDHK1 and PDH that was associated with an upregulated glycolytic profile compared to BAP1 wild-type UM cells. Suppressing PDHK1-PDH phosphorylation decreased glycolytic capacity and cell growth, and induced cell cycle arrest of BAP1 mutant UM cells. Our results suggest that PDHK1-PDH phosphorylation is a causative factor of glycolytic phenotypes found in BAP1 mutant UM and propose a therapeutic opportunity for BAP1 mutant UM patients.",
author = "Anna Han and Vivian Chua and Usman Baqai and Purwin, {Timothy J.} and Nelisa Bechtel and Emily Hunter and Manoela Tiago and Erin Seifert and Speicher, {David W.} and Schug, {Zachary T.} and Harbour, {J. William} and Aplin, {Andrew E.}",
note = "Funding Information: The Cancer Center Support Grant 5P30CA056036-17 to the SKCC supported the Microscopy Shared Resource facility. We thank Dr. Bruce Ksander (Schepens Eye Research Institute, Boston, MA), Dr. Martine Jager (Leiden University, Leiden, The Netherlands), and Dr. Sergio Roman-Roman (Institute Curie, Paris, France) for cell lines. We are grateful to Dr. Michael Durante (University of Miami Miller School of Medicine, Miami, FL) for his help with single-cell RNA-Seq data and Dr. Hsin-Yao Tang (The Wistar Institute, Philadelphia, PA) for metabolomic analyses. This work was supported by National Institutes of Health (NIH)/National Cancer Institute (NCI) grants R01 CA196278, R01 CA253977, and P01 CA114046 to AEA. This work also was supported by a Melanoma Research Alliance team science award (#559058) to AEA and JWH. The Wistar Proteomics and Metabolomics Facility was supported by P30CA010815, P01CA140043, and S10OD023586. Further support was from the American Association for Cancer Research (AACR)/Ocular Melanoma Foundation (OMF) awarded to AH. Funding Information: AEA reports receiving a commercial research grant from Pfizer Inc. (2013–2017) and has ownership interest in patent number 9880150. JWH is the inventor of intellectual property related to prognostic testing for uveal melanoma. He is a paid consultant for Castle Biosciences, licensee of this intellectual property, and he receives royalties from its commercialization. The other authors disclose no potential conflicts of interest. Publisher Copyright: {\textcopyright} 2021, The Author(s), under exclusive licence to Springer Nature Limited.",
year = "2022",
month = feb,
day = "18",
doi = "10.1038/s41388-021-02154-0",
language = "English (US)",
volume = "41",
pages = "1129--1139",
journal = "Oncogene",
issn = "0950-9232",
publisher = "Nature Publishing Group",
number = "8",
}